法罗培南联合利福平抗结核全血杀菌活性试验
该随机全血杀菌活性试验将健康志愿者分为三组,分别接受单剂口服法罗培南+阿莫西林/克拉维酸、利福平或三者联合。结果显示法罗培南单用无杀菌活性,可能与血药浓度低于MIC有关;联合利福平在给药后第一小时显示协同趋势,但整体差异未达统计学显著。
要点
- 法罗培南单用对结核分枝杆菌无全血杀菌活性。
- 法罗培南联合利福平在给药后第一小时显示协同趋势。
- 法罗培南血药浓度相对MIC偏低可能影响疗效。
核心结论
- 法罗培南单用无抗结核活性,可能与血浆浓度相对MIC不足有关。
- 法罗培南与利福平联用提示有 modest 协同作用,值得进一步临床试验。
研究设计与样本
- 随机全血杀菌活性试验,健康志愿者分为三组。
- 法罗培南+阿莫西林/克拉维酸组 n=8;利福平组 n=14;联合组 n=14。
- 单剂口服给药,采血至给药后8小时,用LC-MS/MS测药物浓度,全血接种Mtb后72小时评估cfu变化。
主要发现
- 法罗培南+阿莫西林/克拉维酸组累积WBA为0.02 Δlog cfu,与零变化比P=0.99。
- 8小时累积WBA:利福平组 -0.19 ± 0.03 Δlog cfu,联合组 -0.26 ± 0.03 Δlog cfu,组间P=0.180。
- 给药后第一小时联合组与利福平组差异显著,P=0.032。
- 法罗培南 Cmax 为5.4 mg/L,AUC为16.2 mg·h/L;Mtb H37Rv的MIC为5-10 mg/L。
临床怎么用
- 法罗培南不宜单用于结核病治疗。
- 法罗培南联合利福平的协同作用需进一步临床研究验证。
局限性
- 样本量小,各组n=8至14。
- 仅为全血杀菌活性替代终点,非临床疗效终点。
- 单剂给药,未评估多次给药或长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Faropenem has in vitro activity against Mycobacterium tuberculosis (Mtb) and shows synergy with rifampicin. We tested this in a whole-blood bactericidal activity (WBA) trial. METHODS: We randomized healthy volunteers to receive a single oral dose of faropenem (600 mg) with amoxicillin/clavulanic acid (500/125 mg) ( n = 8), rifampicin (10 mg/kg) ( n = 14) or the combination rifampicin + faropenem + amoxicillin/clavulanic acid ( n = 14). Blood was drawn at intervals to 8 h post-dose. Drug levels were measured using LC-tandem MS. WBA was measured by inoculating blood samples with Mtb and estimating the change in bacterial cfu after 72 h. Trial registration: ClinicalTrials.gov (NCT02393586). RESULTS: There was no activity in the faropenem + amoxicillin/clavulanic acid group (cumulative WBA 0.02 Δlog cfu; P = 0.99 versus zero change). There was a suggestion of a trend favouring the rifampicin + faropenem + amoxicillin/clavulanic acid group at 8 h (cumulative WBA -0.19 ± 0.03 and -0.26 ± 0.03 Δlog cfu in the rifampicin and rifampicin + faropenem + amoxicillin/clavulanic acid groups, respectively; P = 0.180), which was significant in the first hour post-dose ( P = 0.032). Faropenem C max and AUC were 5.4 mg/L and 16.2 mg·h/L, respectively, and MIC for Mtb H37Rv was 5-10 mg/L. CONCLUSIONS: Faropenem is not active when used alone, possibly due to inadequate plasma levels relative to MIC. However, there was a suggestion of modest synergy with rifampicin that may merit further testing in clinical trials.
引用
- Gurumurthy M, Verma R, Naftalin CM, et al. Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. J Antimicrob Chemother. 2017. PMID: 28333342. doi:10.1093/jac/dkx081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。